ArticleNature cancer2024
An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy.
Open access · hybridAbstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 55 citations in OpenAlex.
- Intratumoral T cell activation kills tumors regardless of T cell specificity.Nature immunology · 2026Article
- Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment.Advanced healthcare materials · 2026Review
- HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells.Nature biomedical engineering · 2026Article
- The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice.Nature communications · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4Molecular therapy. Oncology · 2026Article
- Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.Science advances · 2026Article
- Recent advances in the construction of humanized animal models and applications in translational medicine.Animal models and experimental medicine · 2026Review
- Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.Nature cancer · 2026Review
- Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.Chinese medical journal · 2026Review
- PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy.Molecular cancer · 2026Review
- Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8Journal for immunotherapy of cancer · 2026Article
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- Article
- Review
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
- Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Signal transduction and targeted therapy · 2025Article
- IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 1 country.
Xiangyu Chen *Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.
Jing Zhao *Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Shuai Yue *Institute of Immunology, Third Military Medical University, Chongqing, China.
Ziyu Li *Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
Xiang Duan *The State Key Laboratory of Pharmaceutical Biotechnology, National Resource Center for Mutant Mice, MOE Key Laboratory of Model Animals for Disease Study, MOE Engineering Research Center of Protein and Peptide Medicine, Chemistry and Biomedicine Innovation Center, Model Animal Research Center, Medical School of Nanjing University, Nanjing, China.
Yao LinInstitute of Immunology, Third Military Medical University, Chongqing, China.
Yang YangGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Junjian HeInstitute of Immunology, Third Military Medical University, Chongqing, China.
Leiqiong GaoInstitute of Immunology, Third Military Medical University, Chongqing, China.
Zhiwei PanInstitute of Immunology, Third Military Medical University, Chongqing, China.
Xiaofan YangDermatology Hospital, Southern Medical University, Guangzhou, China.
Xingxing SuDepartment of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Min HuangKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Xiao LiKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Ye ZhaoKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Xuehui ZhangKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Zhirong LiInstitute of Immunology, Third Military Medical University, Chongqing, China.
Li HuInstitute of Immunology, Third Military Medical University, Chongqing, China.
Jianfang TangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Yaxing HaoInstitute of Immunology, Third Military Medical University, Chongqing, China.
Qin TianDermatology Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0002-7681-2115
Yifei WangInstitute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.
Lifan XuInstitute of Immunology, Third Military Medical University, Chongqing, China.
Qizhao HuangInstitute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.
Yingjiao CaoGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Yaokai ChenDepartment of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Yan LiThe State Key Laboratory of Pharmaceutical Biotechnology, National Resource Center for Mutant Mice, MOE Key Laboratory of Model Animals for Disease Study, MOE Engineering Research Center of Protein and Peptide Medicine, Chemistry and Biomedicine Innovation Center, Model Animal Research Center, Medical School of Nanjing University, Nanjing, China. yanli@nicemice.cn.ORCID 0000-0001-7612-3953
Fan BaiBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, China. fbai@pku.edu.cn.ORCID 0000-0001-6119-8936
Guozhong ZhangKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China. zhanggz@cau.edu.cn.ORCID 0000-0002-8200-312X
Lilin YeChangping Laboratory, Beijing, China. yelilinlcmv@tmmu.edu.cn.ORCID 0000-0003-0778-3311
Army Medical University · CNChina Agricultural University · CNSouthern Medical University · CNChongqing Medical University · CNModel Animal Research Center · CNChongqing Public Health Medical Center · CNPeking University · CN
Funding
National Natural Science Foundation of China (National Science Foundation of China) 32070942National Natural Science Foundation of China (National Science Foundation of China) 32300785
Abstract
Tumor-specific T cells are crucial in anti-tumor immunity and act as targets for cancer immunotherapies. However, these cells are numerically scarce and functionally exhausted in the tumor microenvironment (TME), leading to inefficacious immunotherapies in most patients with cancer. By contrast, emerging evidence suggested that tumor-irrelevant bystander T (T
Indexed as
Epitopes, T-LymphocyteImmunotherapyNeoplasmsOncolytic VirusesSARS-CoV-2Tumor MicroenvironmentAnimalsAntigens, NeoplasmCell Line, TumorCOVID-19FemaleHumansMiceOncolytic VirotherapyT-LymphocytesXenograft Model Antitumor AssaysAntigens, NeoplasmEpitopes, T-Lymphocyte
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.